Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Preliminary data from double-blind Phase IIb trial in 276 RA patients showed that 1 of 4 TRU-015 doses (800 mg) met
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury